Market Closed -
Other stock markets
|
Pre-market 07:05:46 am | |||
310.7 USD | -0.10% | 310.4 | -0.10% |
Jul. 02 | Alvotech Says Study on Proposed Biosimilar to Prolia, Xgeva Meets Primary Endpoints | MT |
Jun. 27 | Argus Raises Amgen's Price Target to $340 From $300 | MT |
Evolution of the average Target Price on Amgen Inc.
Price target over the last 5 years
History of analyst recommendation changes
Analysts' Consensus
Consensus detail
Consensus revision (last 18 months)
Analysts covering Amgen Inc.
RBC Capital Markets | |
HSBC | |
Redburn Atlantic | |
Mizuho Securities | |
UBS | |
Deutsche Bank Securities | |
William Blair & Co. | |
Leerink Partners | |
Barclays | |
Morgan Stanley | |
BMO Capital | |
Goldman Sachs | |
TD Cowen | |
Oppenheimer | |
Baird | |
Daiwa Securities | |
Truist Securities | |
Argus | |
Jefferies & Co. | |
Credit Suisse | |
DA Davidson | |
Piper Sandler | |
Wells Fargo Securities | |
SVB Securities LLC | |
Cowen | |
Atlantic Equities | |
BofA Securities | |
SVB Leerink | |
JPMORGAN | Cory Kasimov |
RBC | Kennen Mackay |
EPS Revisions
- Stock Market
- Equities
- AMGN Stock
- Consensus Amgen Inc.